PR Business

PharmaReview provides copy review services to the life science industry. Copy review is an important and time-consuming job for thousands of professionals. We ensure that materials, whether internal or external, promotional or non-promotional, are ready for internal review and rapid progression to certification.

From April 2021 to April 2022 we have grown our team from 20 to 60 employees, and continue to recruit.

CopyReview Icon

CopyReview

We facilitate rapid, smooth and cost-effective development and approval of all materials; releasing our clients’ resources to be used more productively elsewhere. Benchmarking studies have demonstrated that errors in material are the single largest cause of repeat review cycles. These repeat cycles squeeze deadlines, increase your costs and often demand longer working hours from the entire development team.

Hide this accordion

test

PharmaReference Icon

PharmaReference

Accurate referencing requires a specialised skillset. We are dedicated to excellence in this area and regard our service as the benchmark of best practice. By offloading this task to our professionals you can release resources and increase productivity.

Hide this accordion

hide

ProcessDesign Icon

ProcessDesign

We are experts and we recognise that many of our clients are experts too! We have developed a model that ensures that every expert’s voice is heard and that time is not wasted on repeat review rounds.

We know that copy review is most efficient when the process is right. Once we are familiar with your internal SOP we can work with you on Veeva to ensure that you have the most efficient process in place.

Hide this accordion

test

Our Partners

 

PharmaReview’s partnership with Bridgepoint Growth

 

 

For further information:

James Murray
Bridgepoint
Tel: +44 (0)207 034 3555
Email: james.murray@bridgepoint.eu

Tessa Pugh
Pharmareview
Tel: +44 (0)7738565573
Email: tessa@pharmareview.com

About Bridgepoint

Bridgepoint is an international alternative asset management firm. With over €32 billion of assets under management, it is currently focused on private equity and private debt:

  • Its private equity funds typically focus on investing in well managed companies in attractive sectors; helping companies and management teams by investing in expansion, operational transformation or via consolidating acquisitions;
  • Its private debt activities are implemented by Bridgepoint Credit which invests across the capital structure through three complementary strategies - direct lending, credit opportunities and senior debt.

Bridgepoint has offices in Amsterdam, Frankfurt, London, Luxemburg, Madrid, New York, Paris, San Francisco, Shanghai and Stockholm.

See www.bridgepoint.eu